Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18502027 | 0.92 | L3MBTL3 (0.66) | CHRM4HRH3L3MBTL3L3MBTL1MCHR2 | |
| SCHEMBL17194188 | 0.91 | L3MBTL3 (0.67) | CHRM4HRH3L3MBTL3L3MBTL1MCHR2 | |
| SCHEMBL10727405 | 0.90 | L3MBTL3 (0.61) | HRH3L3MBTL3L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL18502049 | 0.89 | L3MBTL3 (0.61) | CHRM4HRH3L3MBTL3L3MBTL1SLC2A1 | |
| SCHEMBL18502077 | 0.88 | L3MBTL3 (0.60) | CHRM4HRH3L3MBTL3L3MBTL1SLC2A1 | |
| SCHEMBL18502073 | 0.88 | L3MBTL3 (0.60) | CHRM4HRH3L3MBTL3L3MBTL1SLC2A1 | |
| SCHEMBL17194307 | 0.87 | CHRM4 (0.64) | CHRM4SMN1; SMN2MCHR2MCHR1SLC6A2 | |
| SCHEMBL14430677 | 0.87 | CHRM4 (0.62) | CHRM4HRH3L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL18507054 | 0.86 | CHRM4 (0.57) | CHRM4L3MBTL3L3MBTL1SMN1; SMN2MCHR2 | |
| SCHEMBL18502053 | 0.86 | KDM4E (0.61) | CHRM4HRH3L3MBTL3L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131890-B1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | PASTEUR INSTITUT KOREA (KR) | 2019-04-24 | — | — | EP | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | CHRM4 4630/4885HRH3 2108/4885L3MBTL3 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.